Shawn Cline Tomasello

Ms. Tomasello joined Gamida Cell’s board of directors in June 2019, bringing extensive experience in leading successful commercial activities at several pharmaceutical companies. Most recently, she served as chief commercial officer of Kite Pharma, now part of Gilead Sciences, where she oversaw the global commercialization of Yescarta®, the first approved CAR-T therapy for non-Hodgkin lymphoma. Prior to joining Kite, Ms. Tomasello was chief commercial officer of commercial and medical affairs at Pharmacyclics, now part of AbbVie, where she led commercial and medical affairs activities for Imbruvica®. Ms. Tomasello currently serves on the boards of Mesoblast Limited, UroGen Pharma, Diplomat Pharmacy, Centrexion Therapeutics and Oxford BioTherapeutics.

Ms. Tomasello holds a bachelor’s degree in marketing from the University of Cincinnati and an MBA from Murray State University.